Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Positive save search
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
Published: 2024-04-08 (Crawled : 11:00) - globenewswire.com
INZY | $4.65 -4.12% -4.3% 410K
|
Health Technology
|
| O: 2.2%
H: 7.69%
C: -9.69%
inz-701 pharma positive ongoing trials topline
Syndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
Published: 2024-04-08 (Crawled : 11:00) - prnewswire.com
SNDX | $20.75 -2.49% -2.55% 1.7M
|
Health Technology
|
| O: 3.35%
H: 0.0%
C: -1.34%
gment-101 positive leukemia trial
Positive Results from Phase 3 OPTIMIZE-1 Trial of Once Daily OCS-01 for the Treatment of Inflammation and Pain Following Cataract Surgery Presented at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
Published: 2024-04-08 (Crawled : 11:00) - biospace.com/
OCS 6 d | $11.9 -0.83% -0.08% 33K
|
n/a
|
| O: 0.36%
H: 0.18%
C: -2.76%
ocs-01 positive treatment for meeting trial results
Ionis presents positive results from Phase 3 Balance study of olezarsen for familial chylomicronemia syndrome
Published: 2024-04-07 (Crawled : 16:20) - prnewswire.com
IONS | $40.91 -1.52% -1.49% 1.2M
|
Health Technology
| Email alert
Add to watchlist
positive for results study
Ocular Therapeutix™ Announces Positive Phase 2 PAXTRAVA™ Glaucoma Data at the American Society of Cataract and Refractive Surgery 2024 Annual Meeting
Published: 2024-04-06 (Crawled : 16:20) - globenewswire.com
OCUL | $7.58 -2.7% -2.77% 980K
|
Health Technology
| Email alert
Add to watchlist
glaucoma ocular positive meeting
Natera Announces Positive Surveillance Analysis from the Randomized Phase III IMvigor011 Trial in Muscle-Invasive Bladder Cancer
Published: 2024-04-05 (Crawled : 12:30) - biospace.com/
NTRA | $90.33 0.01% 0.01% 690K
|
Health Services
|
| O: 2.12%
H: 4.35%
C: 2.25%
bladder positive cancer trial
Protara Therapeutics Announces Positive Three-Month Data from TARA-002 Clinical Program in NMIBC
Published: 2024-04-05 (Crawled : 12:00) - globenewswire.com
TARA | $2.75 -3.51% -3.64% 170K
|
Health Technology
|
| O: 16.92%
H: 11.06%
C: -22.77%
tara-002 positive program therapeutics
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410—a Modifier Gene Therapy—in Phase 1/2 ArMaDa Study for Geographic Atrophy
Published: 2024-04-05 (Crawled : 11:00) - globenewswire.com
OCGN | News A | $1.44 -9.43% -10.42% 6.9M
|
Health Technology
|
| O: 1.92%
H: 0.0%
C: 0.0%
ocu410 armada review positive for study
Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
TPST | $3.26 -2.69% -2.76% 350K
|
Manufacturing
|
| O: 8.39%
H: 2.71%
C: -12.96%
tpst-1120 tumors positive cancer publication research communications trial advanced
Biora Therapeutics Achieves Positive Interim Results for Clinical Trial of BT-600, Advancing NaviCap™ Platform Development
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
BIOR | $0.6421 3.4% 2.98% 320K
|
Health Care and Social Assistan...
|
| O: 1.34%
H: 0.0%
C: -4.21%
bt-600 positive trial therapeutics results platform
Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer
Published: 2024-04-04 (Crawled : 12:00) - globenewswire.com
CADL | $5.44 -7.64% -8.57% 820K
|
|
| O: 26.87%
H: 276.85%
C: 215.27%
can-2409 positive cancer pancreatic trial therapeutics
Mirum Pharmaceuticals’ LIVMARLI (maralixibat oral solution) Receives Positive Reimbursement Recommendation by Canada’s CADTH for Patients with Cholestatic Pruritus in Alagille Syndrome
Published: 2024-04-02 (Crawled : 22:00) - biospace.com/
MIRM | $23.85 -0.67% -0.59% 330K
|
Health Technology
|
| O: -1.3%
H: 0.7%
C: 0.36%
pruritus positive livmarli
CYduct Diagnostics Announces Positive Study Results for Biomarker Combinations in the Assessment of Breast Cancer
Published: 2024-04-02 (Crawled : 14:30) - biospace.com/
CYDX | $0.41 -14.15% 290
|
n/a
| Email alert
Add to watchlist
breast biomarker positive cancer diagnostics results study
Petros Pharmaceuticals Reports Positive Results in an Initial Cohort Two-Arm Self-Selection (Phase 2-Equivalent) Study for STENDRA(R) (avanafil) as it Pursues OTC Status
Published: 2024-04-02 (Crawled : 14:30) - biospace.com/
PTPI | $0.689 -2.27% -2.32% 460K
|
| Email alert
Add to watchlist
positive pharmaceuticals results study
C-Bond Systems Reports 2023 Highlights Including Record Revenue and Positive Net Income; Company to Host Conference Call on April 3rd
Published: 2024-04-02 (Crawled : 12:30) - globenewswire.com
CBNT | $0.0042 7.69% 122.22% 950K
|
Manufacturing
|
| O: -11.63%
H: 7.89%
C: 7.89%
conference company revenue positive
Genprex Collaborators Publish Positive Preclinical Data with NPRL2 Gene Therapy Utilizing Oncoprex® Delivery System
Published: 2024-04-02 (Crawled : 12:30) - prnewswire.com
GNPX | $2.21 -3.91% -1.77% 21K
|
Health Technology
|
| O: -5.72%
H: 7.14%
C: 1.43%
oncoprex positive system preclinical therapy
Roivant Announces Positive NEPTUNE Study Results for Brepocitinib in NIU, as well as Board Authorization for up to $1.5 Billion Share Repurchase Program, Including Repurchase of Entire Sumitomo Pharma Stake for $648 Million
Published: 2024-04-02 (Crawled : 11:00) - globenewswire.com
ROIV | $10.45 -2.43% -2.49% 4M
|
Manufacturing
|
| O: 4.79%
H: 3.02%
C: -0.09%
pharma million authorization positive repurchase results study
Ocugen Announces Positive Data and Safety Monitoring Board Review and Initiation of Enrollment in Medium Dose for OCU410ST—a Modifier Gene Therapy—in GARDian Study for Stargardt Disease
Published: 2024-04-01 (Crawled : 22:00) - globenewswire.com
OCGN | News A | $1.44 -9.43% -10.42% 6.9M
|
Health Technology
|
| O: -10.0%
H: 0.69%
C: -4.17%
ocu410 disease review positive study
Gritstone bio Announces Positive Preliminary Progression-free Survival and Long-term Circulating Tumor DNA (ctDNA) Data from Phase 2 Portion of Ongoing Phase 2/3 Study of its Personalized Cancer Vaccine, GRANITE, in Front-line Metastatic Microsatellite Stable Colorectal Cancer (MSS-CRC)
Published: 2024-04-01 (Crawled : 20:00) - globenewswire.com
GRTS | $0.7452 -3.46% -3.64% 3M
|
Health Technology
|
| O: -48.62%
H: 5.38%
C: -7.69%
positive cancer ongoing tumor dna study
Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1b EQUALISE Study of Itolizumab in Lupus Nephritis
Published: 2024-04-01 (Crawled : 19:00) - biospace.com/
EQ | $1.79 -3.24% 0.0% 93K
|
Health Technology
|
| O: -1.73%
H: 0.0%
C: -7.05%
lupus positive topline study
Gainers vs Losers
| 57% | 43% |
Top 10 Gainers
INVO | $1.82 139.47% 56.82% 220M
|
Health Technology
SINT | $0.0365 59.39% 37.26% 470M
|
Health Technology
WISA 4 | $9.19 50.66% 33.7% 65M
|
Electronic Technology
EDBL | News | $6.66 46.37% 32.39% 13M
|
GCTK | $0.715 36.27% 26.62% 600K
|
Manufacturing
TCON | $2.33 36.26% 26.61% 2M
|
Health Technology
TIRX | $0.48 6.43% 24.58% 4.8M
|
KZIA | $0.3442 18.28% 23.42% 290K
|
Health Technology
VNDA | News | $5.23 29.14% 22.56% 24M
|
Health Technology
ATNF | $1.91 29.05% 22.51% 310K
|
Your saved searches
Save your searches and get alerts when important news are released.